Lilly to Present Pivotal Phase 3 Study Results for Investigational Psoriasis Treatment at 23rd World Congress of Dermatology (NYSE:LLY)

INDIANAPOLIS, June 4, 2015 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will showcase results from three pivotal Phase 3 studies investigating ixekizumab for the treatment of moderate-to-severe plaque psoriasis at the 23^rd World Congress of Dermatology in Vancouver, British Columbia, June 8-13.

A total of nine presentations, including seven oral presentations, will report results from the UNCOVER-1, 2 and 3 clinical studies and a separate patient survey. Phase 3 data to be presented from the UNCOVER studies include efficacy and safety results comparing ixekizumab to etanercept and placebo, in addition to quality-of-life improvements observed in patients treated with ixekizumab. Patient survey data to be presented examined the impact psoriasis symptoms have on touch avoidance and quality of life.

Lilly to Present Pivotal Phase 3 Study Results for Investigational Psoriasis Treatment at 23rd World Congress of Dermatology (NYSE:LLY)